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ABSTRACT 
Background: Angiogenesis plays an important role in progression of colorectal carcinoma 
(CRC). Vascular endothelial growth factor (VEGF) is the predominant angiogenic factor in CRC 
and plays important role in cell mitosis, change in cell shape and increases vascular 
permeability. Vascular endothelial growth factor is expressed in approximately 50% of CRCs, 
and considered an important angiogenic factor in growth and development of CRC. In this study, 
we examined VEGF serum levels to asses corelation between serum VEGF levels and size of 
CRC tumors. Patients and Methods: This cross sectional study involved 17 CRC patients with 
stage I, II, III. who had undergone large bowel resection at Karyadi Hospital and had not 
chemotherapy. Size of tumors grading system according to TNM system based on abdominal CT, 
whether serum levels of VEGF was assessed by ELISA.  Results: In this study, we found the 
grading tumor size T1, T2 and T3 was 23,5%, 29,4 % and 47,1 % respectively. Significant 
statistical correlation (p=0.001) was found between serum VEGF levels and size tumors of CRC 
with strong relationship (rho>0,7). Conclusion: This study showed a correlation between serum 
VEGF levels and size of colorectal cancer tumors. Whether  VEGF levels is affected by surgical 
procedure, we need further study to evaluate serum VEGF levels before surgical and tumor size 
according to treatment response. 
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Colorectal cancer is the second most common 
cancer in the world. Colorectal cancer incidence 
rates is more prevalent in developed countries 
such as Australia, New Zealand, Canada and 
USA. In the United States, colorectal cancer is the 
second leading cause of death among those 
developed countries. In 2014, an estimated 
136.830 people were diagnosed with colorectal 
cancer and 50.310 died. It is estimated that 
approximately 95270 new cases of large bowel 
cancer and 39220 new cases of colorectal cancer 
are diagnosed in 2016 (1-4). 
Colorectal cancer is the abnormal growth of cells 
originates in the colon and the rectum. Colorectal 
cancer cells growth and development need 
vascularization to support food supply 
(angiogenesis) (5, 6). 
Angiogenesis process is the formation of new 
blood vessels from the preexisting vasculature. 
Angiogenesis is a vital process in tumor growth 
and development and Vascular Endothelial 
Growth Factor (VEGF)  is a potent stimulator in 
the angiogenic response (7). 
VEGF contributes to tumor growth due to its 
capacity to induce blood vessels permeability 
(6).VEGF is the target of anticancer therapy 
because of its fundamental role in tumor growth 
(8). Although tumor size remains a major 
prognostic value in many other solid organs 
cancer, its value in colon cancer may have long 
been neglected. In additional to our knowledge, 
the aim of this study is to determine the 
association of the serum Vascular Endothelial 
Growth Factor (VEGF) levels with tumor size in 
colorectal cancer. 
 
METHODS 
Sampels 
Blood samples were taken from 17 colorectal 
cancer patients who had undergone large bowel 
resection at Karyadi Hospital. No patients had 
had previous malignant disease nor had received 
chemotherapy or radiotherapy. Blood samples 
were taken, at the time about 2 weeks after 
surgery.  
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Five cc blood was taken into a into serum 
separator tubes (SST) for serum analysis, and 
shaken to homogeneous. Wait for 30 -45 minutes 
until clothing. Samples were centrifuged at 3000 
rpm for 15 minutes. The samples were stored at 
−20°C until assay by ELISA (Quantine R&D 
America). Using calibrator diluent RD5K, the 
minimum detectable dose of VEFG by ELISA is 
typically less than 5.0 pg/ml. All of the samples 
will sent with dryice to Prodia central laboratory 
in Jakarta. 
All specimens were systematically reevaluated 
by expert pathologist in Karyadi hospital.  
Tumour staging was performed according to the 
TNM stage classification American Joint 
Committee on Cancer system 7th (2010) based on 
contrast abdominal CT. 
 
Study Design 
This was a cross-sectional study conducted over 
a period of 3 months at RSUP Dr. Kariadi 
Semarang, 17 patients were included. Correlation 
test was used to assess the association between 
the serum VEGF levels and tumor size in 
colorectal cancer. 
Statistical Analysis 
All collected data were tabulated and calculated 
using SPSS v.16, presented in numerical data, 
median and its variations.Spearman’s rank test 
was used for the correlation analysis. A p-value 
<0.05 was considered statistically significant.  
 
RESULTS 
This study was conducted over a period of 3 
months, a total of 17 samples were studied, 
consisted of 10 males (58,8%) and 7 females 
(41,2%). The age range of the subjects varied 
between 31 years and 81 years. According to age 
category, the subjects were divided into ≤ 50 
years; 51-60 years; 61-70 years; 71-80 years; and 
>80 years with a count of 7(41,2%); 4(23,5%); 
4(23,5%); 1 (5,9%), and 1(5,9%) respectively. 
In this study we found tumor size of T4 in 8 
subjects (47,1%), T3 in 5 subjects (29,41%), and T2 
in 4 subjects (23,52%).  Clinicopathologicalof 
samples are adenocarcinoma. Colorectal cancer 
stages of the subjects consisted of stages I to III 
who underwent surgery and never received 
chemotherapy All pertinent clinical and 
histopathological data of the patients are 
summarised in Table I. 
 
Table1.Characteristics of the study population 
Variables N(%) Mean ±SD Median  
(Minimum-Maximum) 
Gender 
Male 
Female 
 
Age  (years) 
≤ 50   years 
51-60 years 
61-70 years 
71-80 years 
>80    years 
 
Tumor size 
       T2 
       T3 
       T4    
 
Cancer stage 
I 
IIA 
IIC 
IIIA 
IIIB 
IIIC 
 
 
10 (58,8%) 
7  (41,2%) 
 
 
7 (41,2%) 
4 (23,5%) 
4 (23,5%) 
1 (5,9%) 
1 (5,9%) 
 
 
4 (23,5%) 
5 (29,4%) 
8 (47,1%) 
 
 
 2 (11,8%) 
1 (5,9%) 
1 (5,9%) 
2 (11,8%) 
10 (58,8%) 
1 (5,9%) 
 
 
 
 
 
 
53,71 ±13,959 
 
 
 
 
 
 
 
 
 
 
 
308  ± 263 
729  ± 0 
517  ± 0 
192  ± 101 
762  ± 479 
1809 ± 0 
 
 
 
 
 
 
 
 
 
 
 
 
193 (120-494) 
356 (276-973) 
  855 (357-1809) 
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This study found significant 
association between serum VEGF levels with 
tumor size in colorectal cancer P= 0,001 
(P<0,05) with strong correlation (rho >0,7).
 
Tumor size 
 
DISCUSSION 
This study involved 17 colorectal cancer 
patients stages I, II, and III who underwent 
surgery and never received chemotherapy. 
Several studies have shown that colorectal cancer 
increases with age. Colorectal cancer is rare 
before the age of 40. The risk of developing 
colorectal cancer increases at the age of ≥50 years 
and becomes twice as large as in each subsequent 
decade. This study also found the that colorectal 
cancer rates washigher among the subjects who 
were older than 40 years compared to younger 
subjects, with the youngest participant of 31 
years, and most of the study subjects were from 
the age of 40 - 60 years. 
Vascular Endhotelial Growth Factor (VEGF) is 
endothelial cell-specific mitogen. VEGF is a 
mediator of angiogenesis that plays an important 
role in cell mitosis, cell shape alteration and 
increases vascular permeability.VEGF is involved 
in the growth and development of colorectal 
cancer. VEGF is correlated with the invasion of 
colorectal cancer cells, tumor vascular density, 
metastasis, tumor recurrence and poor prognosis, 
furthermore there is a strong association between 
colorectal cancer with apoptosis and angiogenesis 
(9). Serum VEGF levels in the subjects of this study 
(mean 686,82 ± 516,729 pg/ml). 
Large tumors may have independent prognostic 
significance as a result of several factors. Larger 
tumor size may also be a reflection of biologically 
more aggressive tumor. Although tumor size 
remains a major prognostic value in many other 
solid organs cancer, its value in colon cancer may 
have long been neglected (10). In this study we 
found that tumor size of T4 in 8 subjects (47,1%), 
T3 in 5 subjects (29,41%), and T2 in 4 subjects 
(23,52%).   
VEGF has an effect on the progressivity of 
colorectal cancer. According to several studies, 
increased levels of VEGF is associated with 
increased size of colorectal cancer tumors (10-12).  
This study found significant association 
between serum VEGF levels with tumor size in 
colorectal cancer P= 0,001 (P<0,05) with strong 
correlation (rho >0,7). Increased VEGF tumor 
may be used as an independent prognostic 
parameters in the management of colorectal 
patients stages II and III (13-15). Thisfinding is 
consistent with some previous studies. FerroniP, 
et al in 2005 reported that serum VEGF was 
associated with a large tumor (p = 0.005); another 
study by KemikOzgur et al, in 2011 found an 
association between serum VEGF levels and a 
large tumor with p = 0.0001, elevated serum 
VEGF levels was associated with the development 
of colorectal cancer. This finding is similar to the 
study conducted by Kwon et al's in 2010 with p = 
0.012; Sahasukamal et al study in 2014 also 
revealed the correlation of high serum VEGF 
levels with increased tumor size, high serum 
VEGF levels was associated with poor prognosis 
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and larger tumor size decreased patient survival 
rate by 5 years (10, 11, 13, 15).  
 
CONCLUSION 
The present results demonstrate in This study 
has demonstratethat serum VEGF levels is 
significantly difference inassociated with tumor 
size in colorectal cancerinpreviously untreated 
colorectal cancer patients who never received 
chemotherapy. High level VEGF serum associate 
with the larger the tumor. Surgical procedures 
may affect VEGF levels, so further studies are 
may needed to assess the effect of surgery to 
VEGF alterations. VEGF seems to be an indicator 
of poor prognosis,  as well was correlated with 
tumour size, further studies needed to see 
association between VEGF levels with less 
favourable long-term survival. 
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